Video

Institutional Perspectives in Cancer: Multiple Myeloma - Chaired by Thomas Martin, MD

Institutional Perspectives in Cancer: Multiple Myeloma - Chaired by Thomas Martin, MD

Institutional Perspectives in Cancer: Multiple Myeloma - Chaired by Thomas Martin, MD

The live filming of this virtual event in our IPC series is now on-demand.

OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer management. Attendees will not only improve their knowledge of novel treatment approaches, but also leave the event the with confidence and intent to apply state-of-the-art treatment strategies to care for their patients. Each event is dedicated to the latest research in one of the following therapeutic areas: Breast Cancer, Lung Cancer, GU & Prostate Cancer, Hematology, or Melanoma.

The State of the Science Summits and IPC assemble academic and community-based physicians & healthcare professionals across key disciplines from medical and surgical oncology. Specialist experts serve as faculty for these premier and renowned oncology summits, which focus on the most relevant cancer topics to ultimately improve patient care.

Speakers

  • Thomas Martin, MD | UCSF Helen Diller Family Comprehensive Cancer Center
  • Jeffrey Wolf, MD | UCSF Helen Diller Family Comprehensive Cancer Center
  • Nancy Wong, NP, MSN | UCSF Helen Diller Family Comprehensive Cancer Center
  • Alfred Chung, MD | UCSF Helen Diller Family Comprehensive Cancer Center
  • Sandy Wong, MD | UCSF Helen Diller Family Comprehensive Cancer Center
  • Samantha Shenoy, NP, MSN | UCSF Helen Diller Family Comprehensive Cancer Center

Topics

  • Front-line Treatment Options for Multiple Myeloma
  • Early Relapse MM
  • R/R Multiple Myeloma Treatment
  • Bispecific for Multiple Myeloma Treatment
  • CAR T-Cell Therapy: How Do You Choose and Sequence Between the Available Therapies?
  • Research trials for RRMM: Who Are Good Candidates

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
C. Ola Landgren, MD, PhD
David Samuel Dicapua Siegel, MD
Alfred L. Garfall, MD, MS
Noa Biran, MD
Noa Biran, MD
Alfred L. Garfall, MD, MS
Amrita Krishnan, MD, City of Hope
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Noa Biran, MD
Mohamad Mohty, MD, PhD